Upfront Briefing
Dianthus closed an upsized $719M underwritten offering (with the full option exercised) — a big, loud reminder that the financing window is open, but not exactly subtle.
On the catalyst calendar, Mineralys said the FDA accepted its lorundrostat NDA and set a Dec. 22, 2026 PDUFA date.
And in leadership land, Grail named Josh Ofman CEO as Bob Ragusa retires, which is usually code for a new chapter — and new KPIs.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,672.6 |
(1.5%) |
(2.7%) |
| Nasdaq 100 |
24,533.6 |
(1.7%) |
(2.7%) |
| Russell 2000 |
2,489.0 |
(2.1%) |
(0.8%) |
| Healthcare (XLV) |
150.2 |
(1.8%) |
(3.4%) |
| Biotech (XBI) |
122.6 |
(3.0%) |
+0.9% |
| Nasdaq Biotech (NBI) |
5,746.2 |
(2.7%) |
+0.7% |
| Clinical Trials (BBC) |
41.4 |
(3.6%) |
+10.0% |
|
- Risk-off was macro-led and biotech beta amplified the move: oil moved back above $100, Treasury yields rose, and the market priced fewer Fed cuts, pressuring duration-sensitive healthcare and SMID-cap biotech harder than the broad tape.
- Biotech underperformed defensives: XBI fell (3.0%) and NBI (2.7%) versus the S&P 500 at (1.5%), while Clinical Trials (BBC) dropped (3.6%), showing investors were de-risking the highest-volatility development exposure first.
The Big 3
|
1
|
Dianthus closes upsized $719M underwritten public offering
|
- Dianthus Therapeutics said it closed an upsized $719 million underwritten public offering at $81.00/share: 8,470,989 shares (incl. 1,157,407 overallotment) plus 402,468 pre-funded warrants.
-
Why it matters:
A $719M close materially de-risks Dianthus’ balance sheet through multiple clinical and strategic inflection points, strengthening execution leverage with investors and potential partners. The trade-off is straightforward: at $81/share, the deal resets dilution math and raises the bar for the next leg of value creation.
- Source: PR
|
|
2
|
Mineralys says FDA accepted lorundrostat NDA; PDUFA set
|
- Mineralys said the FDA accepted its lorundrostat NDA and set a Dec. 22, 2026 PDUFA date; it also disclosed Explore-OSA topline results that missed the AHI primary endpoint while showing blood-pressure lowering.
-
Why it matters:
FDA acceptance starts the regulatory clock on Mineralys’ lead value driver and puts a hard catalyst on the calendar with the Dec. 22, 2026 PDUFA. The Explore-OSA miss matters strategically, but for investors the core question remains whether lorundrostat can convert resistant hypertension positioning into an approvable, commercially credible first label.
-
Source:
PR
|
| 3 | Grail names Josh Ofman CEO as Bob Ragusa retires |
-
Grail said CEO Bob Ragusa will retire and Josh Ofman will succeed him. The transition is set to reset investor messaging and execution expectations at the cancer-screening company.
-
Why it matters:
CEO transitions at Grail are not cosmetic: investors will now look for a reset in execution against the Galleri PMA pathway, evidence generation to support reimbursement, and burn discipline. A leadership change can improve credibility, but it also raises the pressure on cadence and deliverables.
-
Source:
Endpoints
-
More:
PR
|
Everything Else that broke
- Solid eyes accelerated approval as DMD gene therapy hits FDA. — BioCentury
- Tonix reports FY2025 results, highlights TONMYA launch metrics. — PR
- Oruka updates timing for ORKA-001 EVERLAST-A data. — PR
- Erasca cites early activity for ERAS-0015 dose escalation. — PR
- Pfizer is shutting down Pfizer Ignite, its biotech-incubation offering. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
Rumors
-
Abivax denied French-media takeover rumors linking the company to AstraZeneca after the report moved the stock intraday. — Reuters
M&A / BD&L
-
PRISM BioLab, Receptor.AI announce drug discovery collaboration. — PR
-
Enodia Therapeutics acquired Kezar Life Sciences’ preclinical Sec61 protein-degradation assets in a back-ended deal worth up to $128M, including $1M upfront plus milestones and tiered royalties. — 8-K
VC / Private Financings
-
No notable biotech VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- Dianthus closes upsized $719M underwritten public offering. — PR
Academic Corner
- A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial. — Nature Medicine
- Single-dose sleeping sickness drug set for approval. — Nature RDD
|
